Home
About Us
Who We Are
Milestones
Management Team
Scientific Advisory Board
We Believe
Innovative Research and Development
Technology Platform
Pipeline
Partnerships
Cross-Border Partnership
News
Investor Relations
Join Us
Contact Us
CH
|
EN
Health Guard ranked among TOP 10 on the list of "2022 Future Healthcare VB100 - Top 100 Innovative Biomedicine Companies"
2022-06-22
Beijing Health Guard Approved by NMPA to Commence Clinical Trials of the Recombinant 15-Valent HPV Vaccine
2022-03-15
Beijing Health Guard Announces IND Application for the Recombinant 15-valent HPV Vaccine Accepted for Review by NMPA
2021-12-16
Beijing Health Guard Secures over CNY 1 Billion in Pre-IPO Funding
2021-08-06
R-Pharm and Beijing Health Guard entered into collaboration agreements on the development and commercialization of a nonavalent HPV vaccine in Russia
2021-05-30
Beijing Health Guard Completes Series C Financing to Support Phase III Clinical Trials and Commercial Production of Core HPV vaccines
2020-12-25
Beijing Health Guard Announces Enrollment of First Subject in Phase III Clinical Trial of the Nonavalent HPV Vaccine
2020-12-08
Beijing Health Guard Wins BDA’s 2020 High-Value Patent Innovation Award (the First Session)
2020-10-21
Beijing Health Guard Announces Enrollment of First Subject in Phase III Clinical Trials of the Trivalent HPV Vaccine
2020-10-19
Beijing Health Guard’s Chimeric HPV-VLP presenting SARS-COV-2 epitopes. Project Claims Top Prize at “Maker in Beijing 2020”
2020-03-26
Beijing Health Guard Steps Up Efforts in COVID-19 Peptide Vaccine Development
2020-02-18
More
